Vertex Pharmaceuticals Incorporated vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B), while YieldMax Universe Fund of Option Income ETFs trades at $7.72. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| VRTX | YMAX | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $529.59 | $14.00 |
52-Week Low | $366.54 | $7.51 |
Enterprise Value | $116.69B | — |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →